Share on Facebook
Share on Twitter
Share on LinkedIn
Share on Reddit
Share by Email
Print
美女免费一级视频在线观看
Deals:
Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments.
Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth.
Boehringer Ingelheim and Tessellate Bio entered into a research collaboration and global license agreement exceeding $570 million.
Tempus AI signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could be used to develop new cancer drugs.
Repertoire Immune Medicines agreed to an autoimmune deal with Genentech.
Aerovate Therapeutics stockholders approved the Jade Biosciences merger as well as a reverse stock split.
Silexion Therapeutics announced a collaboration with Catalent.
1Cell.Ai and BioSkryb announced a partnership.
Havas announced a strategic investment in Ostro, an agentic AI company for life sciences.
VelaVigo, an antibody discovery team in China, signed its second U.S. biotech deal in less than six months.
Yosi Health announced a partnership with Elation Health through the Elation Health’s Partner Hub.
1STBIO and LigaChemBio announced a strategic R&D and licensing option agreement.
Cybin announced a strategic partnership with Osmind.
MJH Life Sciences announced a strategic alliance partnership between the American College of Cardiology and Pharmacy Times as well as Pharmacy Times Continuing Education.
SixDegrees.org, a nonprofit founded by actor and philanthropist Kevin Bacon, partnered with Advertising Week to launch the Purpose, Produced initiative to match six nonprofit organizations with creative agencies for the development of a pro bono ad campaign.
FDA:
The agency told Vanda Pharmaceuticals recent staff cuts will delay drug hearing decisions by months.
The FDA is suspending a quality control program for testing of fluid milk and other dairy products due to reduced capacity in its food safety and nutrition division.
Novavax said it believes its COVID-19 vaccine is approvable, based on recent conversations with the FDA.
The Department of Health and Human Services issued a Stop Work Order for GeoVax’s investigational COVID vaccine GEO-CM04S1.
The agency alerted health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products.
The FDA is suspending a quality-control program for its food-testing laboratories as a result of staff cuts at HHS.
Sanofi-Regeneron’s Dupixent received the FDA’s nod for a skin condition.
The FDA sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea from a maximum frequency of every 16 weeks to every 24 weeks.
Luminopia received expanded FDA clearance for its amblyopia treatment for children ages eight to 12.
Tagworks Pharmaceuticals announced that the FDA cleared the investigational new drug application for a Phase 1 clinical trial evaluating TGW101.
AbbVie submitted its Biologics License Application to the agency for trenibotulinumtoxinE for the treatment of glabellar lines.
Layoffs:
Mural Oncology cut its workforce by 90%.
Tempest Therapeutics made moves to cut 80% of its workforce.
The CDC’s Reproductive Technology Surveillance and Research Team was a casualty of the DOGE cuts.
Funding rounds:
Elon Musk’s Neuralink is eyeing a fundraising round at an $8.5 billion valuation.
Grove Biopharma pulled together a $30 million Series A funding round.
Cue Biopharma unveiled a $20 million public offering.
OakNorth provided a £5 million loan to U.K. and U.S. medical communications consultancy SCIRIS.
Industry news:
PhRMA announced AstraZeneca joined as a new member.
Walgreens Boots Alliance agreed to pay $300 million to settle a case alleging company pharmacists knowingly dispensed millions of illegal opioid prescriptions over more than a decade and billed Medicare and other federal health care programs for them.
The company also announced an initiative called PharmStart with talent development company Guild to offer prerequisite classes online and paid for in full.
Gilead Sciences reported that a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with an aggressive form of breast cancer.
The Trump administration announced a plan to remove petroleum-based synthetic dyes from the nation’s food supply.
Harvard University filed a federal lawsuit against the Trump administration, arguing that government overreach violated the university’s constitutional rights.
At least three biotech companies said they’ve received orders from the White House to stop their work related to a Biden-era initiative to advance new COVID vaccines.
The Women’s Health Initiative, a decades-old research initiative supported by the National Institutes of Health, will have its government funding reduced this September.
The NIH has scaled back its awards of new grants by at least $2.3 billion since the beginning of the year.
In a key trial, Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of standard-of-care therapy
The number of births in the U.S. increased slightly in 2024 to roughly 3.6 million, according to provisional data from the Centers for Disease Control and Prevention.
Boehringer Ingelheim announced a continued rise in the number of patients it reached, 66 million in 2024 – up 8% from the previous year.
Medical equipment maker Thermo Fisher Scientific cut its annual profit forecast in anticipation of a potential hit from the Trump administration’s tariffs.
Flagship Pioneering launched disease detection company Etiome.
Sanofi posted strong earnings thanks to growing sales of Dupixent.
Ascletis Pharma’s obesity pill was less effective at its high dose than at lower doses in an early-stage trial.
The New England Journal of Medicine received a letter from a top U.S. attorney asking it to respond to alleged bias.
The National Science Foundation canceled research grants related to misinformation and disinformation.
There have been 8,064 reported cases of whooping cough in the U.S., compared with 3,835 for the same time in 2024, according to CDC data.
Merck lowered its full-year profit guidance, citing a charge tied to a recent licensing deal and $200 million in estimated additional costs for tariffs implemented to date.
Akeso and Summit Therapeutics said the combination of its PD-1/VEGF-blocking antibody ivonescimab plus chemotherapy delayed tumor progression in patients with non-small cell lung cancer.
A letter signed by 18 Democratic senators pushed the Trump administration for answers about how it plans to regulate tobacco products and enforce those regulations in light of cuts at the FDA and CDC.
An analysis in Nature may signal the beginnings of a U.S. science brain drain.
Summit Therapeutics released positive lung cancer drug trial results.
A trial conducted at Massachusetts General Hospital found that pairing a drug with behavioral treatments can curb nicotine cravings and withdrawal symptoms and help young people quit e-cigarettes.
BMS beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs.
Through May 23, Dexcom is conducting a nationwide search for the next generation of student-athletes living with diabetes to join its Dexcom U name, image and likeness program.
HealthCentral created Communities, a collection of condition-specific destinations.
Scientists from Western University and the Schmidt Initiative for Long Covid announced the launch of a clinical trial that will test the effectiveness of two anti-inflammatory medicines as potential treatments for long COVID.
